Search Result

Results for "

dm-

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) 5-HT Receptor (6) Acyltransferase (3) ADC Antibody (2) ADC Linker (4) ADC Payload (17) Adenosine Receptor (2) Aldose Reductase (2) Amylases (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (20) Antibody-Oligonucleotide Conjugates (AOCs) (2) Antifolate (1) Apoptosis (4) Autophagy (1) Bacterial (3) Biochemical Assay Reagents (6) Calcium Channel (2) Calmodulin (1) CCR (3) CDK (1) Cytochrome P450 (2) Dipeptidyl Peptidase (9) DNA Alkylator/Crosslinker (3) DNA/RNA Synthesis (1) Dopamine Receptor (3) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (9) Drug-Linker Conjugates for ADC (31) Dystrophin (1) EGFR (3) Endogenous Metabolite (6) Estrogen Receptor/ERR (2) Fatty Acid Synthase (FASN) (1) FBPase (1) FGFR (1) Fluorescent Dye (1) Free Fatty Acid Receptor (3) FXR (1) GABA Receptor (2) GCGR (5) GLP Receptor (6) Glucocorticoid Receptor (1) GLUT (1) Glycosidase (10) GPR109A (2) GPR119 (2) Hapten (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HMG-CoA Reductase (HMGCR) (1) iGluR (5) IKK (3) Insulin Receptor (2) Interleukin Related (4) Isotope-Labeled Compounds (16) Keap1-Nrf2 (1) Ketohexokinase (1) LRRK2 (3) mGluR (2) Microtubule/Tubulin (25) Mineralocorticoid Receptor (1) nAChR (2) NF-κB (3) Organoid (7) P-glycoprotein (5) Parasite (2) PARP (3) Phosphatase (2) Phosphodiesterase (PDE) (2) PI3K (2) PKC (2) PKD (3) Potassium Channel (1) PPAR (2) PROTACs (1) Quinone Reductase (1) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (15) SARS-CoV (1) SGLT (9) Sigma Receptor (1) Small Interfering RNA (siRNA) (2) Sodium Channel (2) Somatostatin Receptor (3) STAT (2) Target Protein Ligand-Linker Conjugates (2) TGF-beta/Smad (1) TGF-β Receptor (7) TNF Receptor (3) Topoisomerase (1) Transferrin Receptor (1) Transmembrane Glycoprotein (2) Vasopressin Receptor (1) VDAC (1) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (107) Cardiovascular Disease (9) Endocrinology (7) Infection (5) Inflammation/Immunology (15) Metabolic Disease (78) Neurological Disease (16)
Click Chemistry:	ADC Synthesis (2) DBCO (2)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) Antisense Oligonucleotides (2) siRNAs (2)

224

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12071

LDN193189 Maximum Cited Publications 83 Publications Verification dm-3189	Organoid TGF-β Receptor	Cancer
LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-19792

Mertansine 25+ Cited Publications dm1; Maytansinoid dm1	Microtubule/Tubulin ADC Payload	Cancer
Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-12071B

LDN193189 dihydrochloride Maximum Cited Publications 83 Publications Verification dm-3189 dihydrochloride	Organoid TGF-β Receptor	Cancer
LDN193189 (DM-3189) dihydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-12454

DM4 5 Publications Verification Ravtansine	Microtubule/Tubulin ADC Payload	Cancer
DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody agent conjugate.

HY-101070

SMCC-DM1 10+ Cited Publications dm1-SMCC	Drug-Linker Conjugates for ADC	Cancer
SMCC-DM1 (DM1-SMCC) is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker SMCC to make antibody agent conjugate (ADC) .

HY-128915

Duocarmycin DM free base	DNA Alkylator/Crosslinker ADC Payload	Cancer
Duocarmycin DM free base, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM free base is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity .

HY-12071A

LDN193189 Tetrahydrochloride Maximum Cited Publications 83 Publications Verification dm-3189 Tetrahydrochloride	Organoid TGF-β Receptor	Cancer
LDN193189 (DM-3189) Tetrahydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-137234

DM-β-CD 2,6-Di-O-methyl-β-cyclodextrin	Biochemical Assay Reagents	Others
DM-β-CD (2,6-Di-O-methyl-β-cyclodextrin) is a cyclic molecule consisting of seven glucose units modified with two methyl groups at the 2- and 6-positions. It is usually used as a solubilizer and carrier for poorly soluble drugs in pharmaceutical preparations. Furthermore, it has applications in analytical chemistry, food science, and environmental remediation due to its ability to form clathrates with various guest molecules, such as aromatic compounds, pesticides, and heavy metals.

HY-101141

sulfo-SPDB-DM4	Drug-Linker Conjugates for ADC	Cancer
sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.

HY-101982

Lys-SMCC-DM1 1 Publications Verification Lys-Nε-MCC-dm1	Drug-Linker Conjugates for ADC	Cancer
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is a agent-linker conjugates for ADC that can inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. T-DM1 is a HER2-targeting ADC with a tubulin polymerization inhibitor DM1. Lys-SMCC-DM1 can be used in the research of breast cancer .

HY-126491

SPP-DM1	Drug-Linker Conjugates for ADC	Cancer
SPP-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP .

HY-B0340

Nefiracetam dm9384; DZL-221	nAChR iGluR mGluR PKC GABA Receptor Calcium Channel	Neurological Disease
Nefiracetam is a cognition-enhancing agent. Nefiracetam is an activator of nAChR, N-methyl-D-aspartate receptor (NMDAR), mGluR5, PKC, gamma-aminobutyric acid (GABA), and N/L-type Ca ²⁺ channels. Nefiracetam promotes neuroplasticity and enhances neuroprotection. Nefiracetam can be used in Alzheimer's disease, epilepsy, and cerebral ischemia research .

HY-136286

MC-DM1	Drug-Linker Conjugates for ADC	Cancer
MC-DM1 is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody agent conjugate (ADC) .

HY-126682

Mal-VC-PAB-DM1 3 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
Mal-VC-PAB-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB .

HY-17550

Sunifiram dm-235	iGluR	Neurological Disease
Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) .

HY-12071G

LDN193189 dm-3189	Organoid TGF-β Receptor	Cancer
LDN193189 GMP is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 (DM-3189) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-126494

DM4-SMCC	Drug-Linker Conjugates for ADC	Cancer
DM4-SMCC is a agent-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker .

HY-132250

MCC-DM1	Drug-Linker Conjugates for ADC	Cancer
MCC-DM1 is a agent-Linker Conjugates for ADC such as Anti-CD22-MCC-DM1. MCC-DM1 can be detected in rat and human plasma, feces, and other tissues .

HY-139441

DM21	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
DM21 is a next-generation linker-payload that combines a maytansinoid microtubule-disrupting payload with a stable tripeptide linker. DM21 is conjugated with a humanized antibody against ADAM9 to obtain IMGC936 .

HY-12460

SPDB-DM4 3 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.

HY-130080

DM3 Maytansinoid dm3	ADC Payload Microtubule/Tubulin	Cancer
DM3 (Maytansinoid DM3), a Maytansine (HY-13674) analog bearing disulfide or thiol groups, and is a tubulin inhibitor. DM3 a cytotoxic moiety of antibody-drug conjugates (ADCs) .

HY-100128

DM1-SMe	Microtubule/Tubulin ADC Payload	Cancer
DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin .

HY-120140

Ganoderic acid DM 1 Publications Verification	Apoptosis PI3K	Metabolic Disease Inflammation/Immunology Cancer
Ganoderic acid DM, a natural triterpenoid isolated from Ganoderma lucidum, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Ganoderic acid DM as a specific inhibitor of osteoclastogenesis .

HY-136261

DM1-PEG4-DBCO	Drug-Linker Conjugates for ADC	Cancer
DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-126693

SC-VC-PAB-DM1	Drug-Linker Conjugates for ADC	Cancer
SC-VC-PAB-DM1 is a agent-linker conjugate for ADC with with potent antitumor activity by using DM1 (Mertansine, a tubulin inhibitor) , linked via the ADC linker SC-VC-PAB .

HY-12071C

LDN193189 hydrochloride 70+ Cited Publications dm-3189 hydrochloride	Organoid TGF-β Receptor	Cancer
LDN193189 (DM-3189) hydrochloride is a potent selective BMP type I receptor (BMP I) inhibitor. LDN193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC₅₀ values of 5 nM and 30 nM, respectively. LDN193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .

HY-P99492

Cantuzumab mertansine SB-408075; huC242-dm1	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1 (HY-19792)) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .

HY-125931

Unifiram dm232	iGluR	Neurological Disease Inflammation/Immunology
Unifiram (DM232) is a AMPA receptor activator and cognitive enhancer. Unifiram activates the AMPA-mediated neurotransmission system. Unifiram reverses NBQX-induced amnesia in the passive avoidance test in mice. Unifiram reverses the antagonistic effect of kynurenic acid on NMDA-mediated [ ³H]NA release in rat hippocampal slices. Unifiram enhances excitatory synaptic transmission in the rat hippocampus in vitro. Unifiram can be used in studies related to amnesia and cognitive dysfunction, including age-related memory decline, neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, multiple sclerosis, schizophrenia, and attention deficit hyperactivity disorder .

HY-100665

Dehydroaripiprazole 1 Publications Verification OPC-14857; dm-14857	5-HT Receptor Dopamine Receptor	Neurological Disease
Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole (HY-14546) and dopamine D₂/D₃ receptor partial agonist. Dehydroaripiprazole also has certain affinity for serotonin 5-HT₁A, 5-HT₂A and 5-HT₂B receptors. Dehydroaripiprazole has antipsychotic activity equivalent to Aripiprazole .

HY-130082

DM4-SMe	ADC Payload Microtubule/Tubulin	Cancer
DM4-SMe is a metabolite of antibody-maytansin conjugates (AMCs) and a tubulin inhibitor, and also a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM4-SMe inhibits KB cells with an IC₅₀ of 0.026 nM. DM4-SMe is a highly toxic metabolite that can be oxidized and detoxified by human liver microsomes .

HY-148818

S-Me-DM4 1 Publications Verification	ADC Payload	Others
S-Me-DM4 is a metabolite of DM4 S-methylated by intracellular enzyme. DM4 (HY-100503) is a microtubule-depolymerizing maytansinoid with strong cytotoxicity. DM4 can be used as an ADC Cytotoxin molecule .

HY-100504

S-methyl DM1	Microtubule/Tubulin ADC Payload	Cancer
S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin with a K_d of 0.93 μM and inhibts microtubule polymerization. S-methyl DM1 potently suppresses microtubule dynamic instability and has anticancer effects .

HY-164669

ADC Control Human IgG1-DM4	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1-DM4 is an isotype control of ADC Human IgG1-DM4. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is SPDB-DM4 (HY-12460).

HY-131246

DM-01	Histone Methyltransferase	Cancer
DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors .

HY-112068

DM-NOFD	HIF/HIF Prolyl-Hydroxylase	Cancer
DM-NOFD is a cell penetrant, prodrug of NOFD a potent and selective inhibitor of an asparaginyl hydroxylase FIH (factor-inhibiting HIF) .

HY-P99493

Cantuzumab ravtansine 1 Publications Verification IMGN242; huC242-dm4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (HY-12454). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .

HY-12454S

DM4-d6	Isotope-Labeled Compounds Microtubule/Tubulin ADC Payload	Cancer
DM4-d₆ is deuterium labeled DM4. DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody agent conjugate.

HY-126789

DM-Nitrophen	Biochemical Assay Reagents	Metabolic Disease
DM-Nitrophen is a photolabile caged calcium compound that acts as a calcium releaser. DM-Nitrophen binds Ca ²⁺ with high affinity and Mg ²⁺ with considerable affinity before photolysis. DM-Nitrophen releases Ca ²⁺ into the cytosol upon ultraviolet light irradiation. DM-Nitrophen induces calcium concentration pulses, triggers cytosolic calcium transients, promotes calcium-dependent exocytosis. DM-Nitrophen can be used for the research of calcium-dependent cellular processes .

HY-130978

Duocarmycin DM	DNA Alkylator/Crosslinker ADC Payload	Cancer
Duocarmycin DM, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity .

HY-159774

ADC Control human IgG1-DM1	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control human IgG1-DM1 is the ADC control, which is composed of Human IgG1 kappa, Isotype Control (HY-P99001) and the linker-payload conjugate SMCC-DM1 (HY-101070) .

HY-153043

DM-CO-(CH2)5-SMe	Drug Metabolite	Cancer
DM-CO-(CH2)5-SMe is an anticancer agent derived from antibody-drug conjugates (ADC) metabolite with cytotoxicity to H1703, H1975, COLO704 and Colo720E cells .

HY-101982A

(Rac)-Lys-SMCC-DM1 (Rac)-Lys-Nε-MCC-dm1	Drug-Linker Conjugates for ADC	Cancer
(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1 (HY-101982). Lys-SMCC-DM1 is a linker-payload component that has the potential to inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1 .

HY-102001

Tomaymycin DM	ADC Payload	Cancer
Tomaymycin DM is a tomaymycin derivative, PBD monomer, and DNA alkylating agent. Tomaymycin DM can serve as a payload in tumor-targeting antibody-conjugated active molecules (ADCs).

HY-100503

Maytansinoid DM4	ADC Payload	Cancer
Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC .

HY-133152

Brexpiprazole S-oxide dm-3411	5-HT Receptor Dopamine Receptor	Neurological Disease
Brexpiprazole S-oxide (DM-3411) is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT_1A and dopamine receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT_2A receptor antagonist with a K_i of 0.47 nM .

HY-126493

DM4-SPDP	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
DM4-SPDP is a Drug-Linker Conjugates for ADC. DM4-SPDP consists of the ADC cytotoxin DM4 (HY-12454) and a linker SPDP (HY-100216). DM4-SPDP can be used for synthesis of ADCs .

HY-126789A

DM-Nitrophen tertasodium	Biochemical Assay Reagents	Metabolic Disease
DM-Nitrophen tertasodium is a photolabile caged calcium compound that acts as a calcium releaser. DM-Nitrophen tertasodium binds Ca ²⁺ with high affinity and Mg ²⁺ with considerable affinity before photolysis. DM-Nitrophen tertasodium releases Ca ²⁺ into the cytosol upon ultraviolet light irradiation. DM-Nitrophen tertasodium induces calcium concentration pulses, triggers cytosolic calcium transients, promotes calcium-dependent exocytosis. DM-Nitrophen tertasodium can be used for the research of calcium-dependent cellular processes .

HY-164303

Val-Cit-PAB-DEA-Duo-DM	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
Val-Cit-PAB-DEA-Duo-DM is a drug-linker conjugate, which consists of the linker Val-Cit-PAB, the spacer DEA and the ADC toxin Duocarmycin DM (Duo-DM) (HY-130978). Val-Cit-PAB-DEA-Duo-DM can be used for the synthesis of ADC molecule .

HY-147094

vc-PABC-DM1	ADC Linker	Cancer
vc-PABC-DM1 used to synthesize an ADC molecule based on utilize disulfide linker. vc-PABC-DM1 can be used to explore serum stability .

HY-143986S1

DM50 impurity 1-d9-1	Drug Metabolite Isotope-Labeled Compounds	Others
DM50 impurity 1-d₉-1 is the deuterium labeled DM50 impurity 1 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1021

Vincamine 1 Publications Verification	Apocynaceae Cardiovascular Disease Alkaloids Classification of Application Fields Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	Free Fatty Acid Receptor
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-120140

Ganoderic acid DM 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Polyporaceae Metabolic Disease Ganoderma lucidum (Leyss. Ex Fr.) Karst. Plants Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis PI3K
Ganoderic acid DM, a natural triterpenoid isolated from Ganoderma lucidum, induces DNA damage, G1 cell cycle arrest and apoptosis in human breast cancer cells. Ganoderic acid DM as a specific inhibitor of osteoclastogenesis .

HY-N0500

Mogroside III	Triterpenes Classification of Application Fields Terpenoids Cucurbitaceae Metabolic Disease Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Disease Research Fields Sweeteners Source Classification Food Research	Glycosidase Autophagy
Mogroside III is a triterpenoid glycoside. Mogroside III exhibits maltase inhibitory effect with an IC₅₀ value of 1.6 mM. Mogroside III enhances oocyte developmental potential by promoting autophagy in cumulus cells. Mogroside III, as the active ingredient of the low-polarity glycoside component (L-SGgly), L-SGgly can increase serum GLP-1 levels, improve insulin resistance, and reduce IL-6 levels, and has hypoglycemic, lipid-regulating and anti-inflammatory effects. Mogroside III can be used for the studies of type 2 diabetes mellitus (T2DM) and assisted reproductive technology .

HY-155157

PF-07247685	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-W004874

2,6-Dimethylhydroquinone M-Xylohydroquinone	Classification of Application Fields Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
2,6-Dimethylhydroquinone is a key metabolic intermediate for the Mycobacterium strain DM1 during the degradation of 2,6-dimethylphenol (2,6-xylenol). 2,6-Dimethylhydroquinone can serve as an indicator for early failures in biological treatment systems .

HY-N8491

Dihydrocarveol	Cymbopogon martini Terpenoids Gramineae Diterpenoids Plants Source Classification	Others
Dihydrocarveol is an anticancer agent. Dihydrocarveol shows inhibitory activity against human colon adenocarcinoma cells (HCT-116, HT-29, COLO320DM) with an IC₅₀ value of 28.31 μM in HCT-116 cells. Dihydrocarveol is promising for research of colon cancer .

HY-155156

PF-07238025	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-107259

23S-Hydroxyl-11,15-dioxo-ganoderic acid DM 23S-Hydroxy-3,7,11,15-tetraoxo-lanost-8,24E-diene-26-oic	Triterpenes Classification of Application Fields Terpenoids Polyporaceae Other Diseases Plants Disease Research Fields Source Classification	Others
23S-Hydroxyl-11,15-dioxo-ganoderic acid DM is a compound isolated from the fruit bodies of Ganoderma lucidum .

HY-N11919

Anticancer agent 149	Phenols Polyphenols Plants Dioscorea membranacea Pierre ex Prain & Burkill Source Classification Dioscoreaceae	Others
Anticancer agent 149 (compound 3) is an anticancer agent isolated from the rhizome of Dioscorea dioscorea (DM). Anticancer agent 149 exhibits selective cytotoxic activity against MCF-7 cells (IC₅₀=31.41 μM) .

HY-B1021R

Vincamine (Standard)	Apocynaceae Alkaloids Structural Classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	Reference Standards Free Fatty Acid Receptor
Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-N14732

Demycarosyl platenomycin dm-PLM	Microorganisms Antibiotics Other Antibiotics Source Classification	Antibiotic Bacterial
Demycarosylplatenomycin (DM-PLM) is an antibiotic with weak activity against Gram-positive bacteria .

HY-W004874R

2,6-Dimethylhydroquinone (Standard) M-Xylohydroquinone (Standard)	Structural Classification Phenols Polyphenols Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
2,6-Dimethylhydroquinone (Standard) is an analytical standard for 2,6-Dimethylhydroquinone (HY-W004874). This product is intended for research and analytical applications. 2,6-Dimethylhydroquinone is a key metabolic intermediate in the degradation of 2,6-xylenol by Mycobacterium strain DM1. 2,6-Dimethylhydroquinone can be used as an early indicator of failure in biological treatment systems.

Cat. No.	Product Name	Chemical Structure

HY-12454S

DM4-d6
DM4-d₆ is deuterium labeled DM4. DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in the preparation of antibody agent conjugate.

HY-143986S1

DM50 impurity 1-d9-1
DM50 impurity 1-d₉-1 is the deuterium labeled DM50 impurity 1 .

HY-133152S

Brexpiprazole S-oxide-d8

Brexpiprazole S-oxide-d₈ (DM-3411 D₈) is a deuterium labeled Brexpiprazole S-oxide (HY-133152). Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with K_is of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM .

HY-14928S1

Lobeglitazone-d4
Lobeglitazone-d₄ is deuterium labeled Lobeglitazone. Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) .

HY-15408S

Trelagliptin-13C,d3
Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin . Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-143987S

DM51 impurity 1-d9
DM51 impurity 1-d₉ is the deuterium labeled DM51 impurity 1 .

HY-143986S

DM50 impurity 1-d9
DM50 impurity 1-d₉ is the deuterium labeled DM50 impurity 1 .

HY-143985S

Maytansinoid DM4 impurity 5-d6
Maytansinoid DM4 impurity 5-d₆ is the deuterium labeled Maytansinoid DM4 impurity 5 .

HY-143992S

Maytansinoid DM4 impurity 2-d6
Maytansinoid DM4 impurity 2-d₆ is the deuterium labeled Maytansinoid DM4 impurity 2 .

HY-143993S

Maytansinoid DM4 impurity 3-d6
Maytansinoid DM4 impurity 3-d₆ is the deuterium labeled Maytansinoid DM4 impurity 3 .

HY-100665S

Dehydroaripiprazole-d8
Dehydroaripiprazole-d₈ is deuterium labeled Dehydroaripiprazole. Dehydroaripiprazole (OPC-14857) is an active metabolite of Aripiprazole. Aripiprazole is an antipsychotic agent and is metabolized by CYP3A4 and CYP2D6 forming mainly Dehydroaripiprazole. Dehydroaripiprazole has with antipsychotic activity equivalent to Aripiprazole .

HY-10450S5

Dapagliflozin-13C6-1
Dapagliflozin- ¹³C₆-1 is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-10450S3

Dapagliflozin-13C6
Dapagliflozin- ¹³C₆ (BMS-512148- ¹³C₆) is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-10450S2

Dapagliflozin-d4
Dapagliflozin-d₄ (BMS-512148-d₄) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-19792S2

Mertansine-d3
Mertansine-d₃ (DM1-d₃) is the deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

HY-19792S

Mertansine-13C,d3

Mertansine- ¹³C,d₃ (DM1- ¹³C,d₃) is the ¹³C- and deuterium labeled Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure